Bone marrow non-mesenchymal mononuclear cells induce functional differentiation of neuroblastoma cells

Phruksaniyom, Chareerut; Dharmasaroja, Permphan; Issaragrisil, Surapol

doi:10.1186/2162-3619-2-9

Cited by 3 publications

(5 citation statements)

References 12 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite these encouraging results, in depth in vitro evidence on the underlying mechanisms of action is largely unknown. The scarce in vitro data on the effect of BMMNCs on regenerative processes showed that BMMNCs exerted protective effects on rat hippocampal brain slices subjected to oxygen and glucose deprivation and that the BMMNC secretome induced neuronal differentiation of SH‐SY5Y neuroblastoma cells . Nonetheless, additional in vitro data supporting the mechanism of action of BMMNC‐based therapy for ischemic stroke are required.…”

Section: Discussion and Perspectivesmentioning

confidence: 99%

“…94 Despite the promising results with BMMNCs in ischemic stroke from preclinical studies, 61-63, 95, 96 in vitro evidence of the effect of BMMNCs on the above-mentioned mechanisms is scarce. 97,98 Therefore, this review will focus on MSCs and iPSCs as readily available sources of stem cells and compare their efficacy and potential to ameliorate the disease outcome in animal models of ischemic stroke. In addition, novel imaging strategies allowing in vivo tracking of transplanted cells and noninvasive evaluation of brain repair following stroke will be discussed.…”

Section: Stem Cell Sources and Mechanisms Of Action For Cell-basedmentioning

confidence: 99%

“…Despite the promising results with BMMNCs in ischemic stroke from preclinical studies, in vitro evidence of the effect of BMMNCs on the above‐mentioned mechanisms is scarce . Therefore, this review will focus on MSCs and iPSCs as readily available sources of stem cells and compare their efficacy and potential to ameliorate the disease outcome in animal models of ischemic stroke.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Stem Cell‐Based Therapies for Ischemic Stroke: Preclinical Results and the Potential of Imaging‐Assisted Evaluation of Donor Cell Fate and Mechanisms of Brain Regeneration

Gervois

Wolfs

Ratajczak

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

Stroke is the second most common cause of death and is a major cause of permanent disability. Given the current demographic trend of an ageing population and associated increased risk, the prevalence of and socioeconomic burden caused by stroke will continue to rise. Current therapies are unable to sufficiently ameliorate the disease outcome and are not applicable to all patients. Therefore, strategies such as cell-based therapies with mesenchymal stem cell (MSC) or induced pluripotent stem cell (iPSC) pave the way for new treatment options for stroke. These cells showed great preclinical promise despite the fact that the precise mechanism of action and the optimal administration route are unknown. To gain dynamic insights into the underlying repair processes after stem cell engraftment, noninvasive imaging modalities were developed to provide detailed spatial and functional information on the donor cell fate and host microenvironment. This review will focus on MSCs and iPSCs as types of widely used stem cell sources in current (bio)medical research and compare their efficacy and potential to ameliorate the disease outcome in animal stroke models. In addition, novel noninvasive imaging strategies allowing temporospatial in vivo tracking of transplanted cells and coinciding evaluation of neuronal repair following stroke will be discussed.

show abstract

Section: Discussion and Perspectivesmentioning

confidence: 99%

Section: Stem Cell Sources and Mechanisms Of Action For Cell-basedmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Stem Cell‐Based Therapies for Ischemic Stroke: Preclinical Results and the Potential of Imaging‐Assisted Evaluation of Donor Cell Fate and Mechanisms of Brain Regeneration

Gervois

Wolfs

Ratajczak

et al. 2016

Medicinal Research Reviews

View full text Add to dashboard Cite

show abstract

“…Stem cells confer neuroprotection through various paracrine mechanisms. Depending on the cellular microenvironment, these cells secrete and regulate a plethora of neurotrophic factors that are essential for the nervous system, like nerve growth factor-β (NGF-β, critical for the development and maintenance of the nervous system [52]), ciliary neurotrophic factor (CNTF, promotes neurogenesis [53]), brain-derived neurotrophic factor (BDNF, major role player in neuronal development as well as synaptic plasticity [53]), glial cell-derived neurotrophic factor (GDNF, plays an important role in striatal dopaminergic transport [54]), and angiopoietin 1 (ANG-1, promotes angiogenesis [55]).…”

Section: Paracrine Effectsmentioning

confidence: 99%

Stem Cell Therapy in Motor Neuron Disease

Sharma¹,

Sane²,

Gokulchandran³

et al. 2020

Novel Aspects on Motor Neuron Disease

View full text Add to dashboard Cite

Motor neuron disease (MND) is an insidious, fatal disorder that progresses with the selective loss of anterior horn cells of the spinal column. Over 150 years since it was first described, various therapeutic approaches have been tested in the quest of a cure but with little success. Current standard therapy only improves lifespan by a few months; palliative care is the only option available for patients. Stem cell therapy is a potent approach for the treatment of this devastating disease. A multitude of vitalizing effects, both paracrine and somatic, a robust safety profile, as well as ease of availability make a strong case for using these cells for therapeutic purposes. Coupled with rigorous rehabilitation, this powerful treatment modality has been shown to slow disease progression, improve quality of life, and increase survival, along with being well tolerated by amyotrophic lateral sclerosis (ALS)/ MND patients. Compelling preclinical as well as clinical evidence abounds that stem cells hold great potential as a therapy for ALS/MND. Although not a definitive solution yet, stem cells have been verified to have slowed and/or halted disease progression in a subset of ALS/MND patients.

show abstract

“…BMMNCs have been known to confer neuroprotection through various paracrine and somatic mechanisms. These cells secrete and regulate a plethora of neurotrophic factors, like ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF) 42 , glial cell-derived neurotrophic factor (GDNF) 43 , β-nerve growth factor (β-NGF) 44 , vascular endothelial growth factor (VEGF) 45 , tumor necrosis factor (TNF)-α and interleukins (IL-1α, IL-β, IL-6, IL-10) 46 , granulocyte-colony stimulating factor (G-CSF) 47 , granulocyte macrophage-colony stimulating factor (GM-CSF) 44 , basic fibroblast growth factor (bFGF) 45 , platelet-derived growth factor-BB (PDGF-BB) 44 and angiopoietin 1 (ANG-1) 48 . Sasaki and colleagues show that BMMNCs can differentiate into a myelinating phenotype in vivo and repair demyelinated CNS 49 .…”

Section: Table 1: Changes In Outcome Measures Over a Period Of 18 Monmentioning

confidence: 99%

Neuroregenerative Rehabilitation Therapy with long-term Lithium in a Male Amyotrophic Lateral Sclerosis Patient: A Case Report.

Sharma

Sane

Pradhan

et al. 2019

ijmsci

View full text Add to dashboard Cite

Various cellular therapies are being increasingly investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease with selective loss of anterior horn cells. Lithium is known to enhance the potency of transplanted cells, while being well tolerated by ALS patients. Additionally, rehabilitation significantly improves outcomes in various neurodegenerative disorders. We present a 47-year-old male patient suffering from ALS for 2 years, whose treatment involved intrathecal transplantation of autologous Bone Marrow-derived Mononuclear Cells and long-term Lithium, followed by multidisciplinary neurorehabilitation, and standard Riluzole treatment. ALS-FRSr score improved from 39 to 41; FIM remained stable at 101; 6MWT distance improved from 396 m to 480 m and Berg Balance score remained stable at 56 over a span of 18 months. Symptomatic improvements were seen in speech, swallow, stamina, walking and muscle strength; fasciculations and cramps reduced drastically. The highlight of this case is the maintenance of the patient’s condition in view of a degenerative prognosis. Cellular therapy along with long term Lithium and holistic rehabilitation, in addition to standard Riluzole treatment- together termed as Neuroregenerative Rehabilitation Therapy- is a novel approach for halting disease progression and qualitatively improving living conditions for ALS patients and caregivers alike.

show abstract

Bone marrow non-mesenchymal mononuclear cells induce functional differentiation of neuroblastoma cells

Cited by 3 publications

References 12 publications

Stem Cell‐Based Therapies for Ischemic Stroke: Preclinical Results and the Potential of Imaging‐Assisted Evaluation of Donor Cell Fate and Mechanisms of Brain Regeneration

Stem Cell‐Based Therapies for Ischemic Stroke: Preclinical Results and the Potential of Imaging‐Assisted Evaluation of Donor Cell Fate and Mechanisms of Brain Regeneration

Stem Cell Therapy in Motor Neuron Disease

Neuroregenerative Rehabilitation Therapy with long-term Lithium in a Male Amyotrophic Lateral Sclerosis Patient: A Case Report.

Contact Info

Product

Resources

About